ClinicalTrials.gg
CompletedNCT04664959Updated Feb 4, 2025Results posted

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

A Phase 3 interventional study of SB16 (Proposed Denosumab Biosimilar) and Prolia® (Denosumab) in Postmenopausal Osteoporosis, sponsored by Samsung Bioepis Co., Ltd.. Completed at 5 sites in Poland. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Samsung Bioepis Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Osteoporosis, Postmenopausal with a site in Poland — none open to participants now, 2 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · Poland.

Enrollment
24th of 36
457 · median 543
Started
2020
the only one that year
Phase 3
27 of 36
none open now
Registered
27th of 36
by date

Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, this one is the 24th largest by enrollment, is the only one that started in 2020, is one of 27 in phase 3, and was the 27th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

None of the 36 studies in Osteoporosis, Postmenopausal with a site in Poland is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Osteoporosis, Postmenopausal with a site in Poland as a file.
02

Study summary

This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis.

Read the detailed description

Subjects will be randomised in a 1:1 ratio to receive either SB16 or Prolia®. At Month 12, subjects in Prolia® treatment group will be randomised again in a 1:1 ratio to either continue on Prolia® treatment or be transitioned to SB16 treatment. Investigational product (60 mg in 1 mL of SB16 or Prolia®) will be given subcutaneously every 6 months up to Month 12, and the last assessment will be done at Month 18.

03

Conditions studied

  • Postmenopausal Osteoporosis
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women who are 55 to 80 years of age at Screening
  • Ambulatory and visually unimpaired to participate in the study at Screening, in the opinion of the Investigator
  • Absolute BMD consistent with T-score at the total hip or lumbar spine of -4 and -2.5 at Screening
  • At least three evaluable vertebrae within L1 to L4, one evaluable femoral neck, and one evaluable hip joint for BMD measurement at Screening
  • Biologic naïve at Screening
  • Body weight of 50 kg and 90 kg at Screening

Exclusion criteria

Exclusion Criteria:

  • One severe or more than two moderate vertebral fractures on spinal X-ray according to Genant classification at Screening
  • History of hip fracture or bilateral hip replacement at Screening
  • Uncorrected vitamin D deficiency at Screening
  • Hypercalcemia or hypocalcaemia at Screening
  • Inadequate haematological function at Screening
  • Inadequate renal or hepatic function at Screening
  • Known allergic reactions, , or intolerance to denosumab or to any ingredients of the IP, including latex allergy or hereditary problems of fructose intolerance at Screening
  • May not tolerate long-term calcium or vitamin D supplementation or subject with malabsorption of calcium or vitamin D supplements, in the opinion of the Investigator, at Screening
  • Use of any of the medications that can affect BMD
  • Use of any non-biologic IP that is not indicated for osteoporosis from another study or use of an device at Screening
  • Non-osteoporosis medical conditions that can affect BMD at Screening
  • Any disease or disorder or laboratory abnormality which, in the opinion of the Investigator, would prevent the subject from completing the study or the interpretation of the study results at Screening and Randomisation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    SB16 (Proposed Denosumab Biosimilar)

    Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.

    Drug: SB16 (Proposed Denosumab Biosimilar)

  • Active comparator
    Prolia® (Denosumab)

    Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months. At Month 12, subjects in Prolia® treatment group will be re-randomised in a 1:1 ratio to either continue on Prolia® treatment or be transitioned to SB16 treatment. After re-randomisation, subjects transited to SB16 group will receive SB16, and subjects remaining in Prolia® group will continue to receive Prolia® at Month 12.

    Drug: SB16 (Proposed Denosumab Biosimilar) · Drug: Prolia® (Denosumab)

Interventions

  • DrugSB16 (Proposed Denosumab Biosimilar)

    Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months. At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously.

  • Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Lumbar Spine BMD at Month 12

    Time frame: Baseline and Month 12

07

Results

Posted Jan 9, 2025

Participant flow

Main Period
Participant flow — Main Period
MilestoneSB16ProliaSB16+SB16Prolia+SB16Prolia+Prolia
Started225232000
Completed206201000
Not completed1931000
Transition Period
Participant flow — Transition Period
MilestoneSB16ProliaSB16+SB16Prolia+SB16Prolia+Prolia
Started00206100101
Completed002069999
Not completed00012

Outcome measures

PrimaryPercent Change From Baseline in Lumbar Spine BMD at Month 12
Time frame:
Baseline and Month 12
Reported as:
Least squares mean · %Change of BMD
Percent Change From Baseline in Lumbar Spine BMD at Month 12
%Change of BMDSB16Prolia
Percent Change From Baseline in Lumbar Spine BMD at Month 125.63 ± 0.2505.30 ± 0.254

Adverse events

Collected over Overall Period (18 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SB160/225 (0%)12/225 (5.3%)116/225 (51.6%)
Prolia Overall0/231 (0%)11/231 (4.8%)107/231 (46.3%)
Prolia+SB160/100 (0%)5/100 (5%)46/100 (46%)
Prolia+Prolia0/101 (0%)3/101 (3%)49/101 (48.5%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventSB16Prolia OverallProlia+SB16Prolia+Prolia
Atrial fibrillationCardiac disorders0/2251/2311/1000/101
Transient ischaemic attackNervous system disorders0/2251/2311/1000/101
NephrolithiasisRenal and urinary disorders0/2251/2311/1000/101
Urethral caruncleRenal and urinary disorders0/2251/2311/1000/101
OsteoarthritisMusculoskeletal and connective tissue disorders1/2251/2311/1000/101
General physical health deteriorationGeneral disorders0/2251/2310/1001/101
CataractEye disorders0/2251/2310/1001/101
Retinal detachmentEye disorders0/2251/2310/1001/101
Intervertebral disc disorderMusculoskeletal and connective tissue disorders0/2251/2310/1001/101
Intervertebral discitisInfections and infestations0/2251/2310/1001/101
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSB16Prolia OverallProlia+SB16Prolia+Prolia
HypocalcaemiaMetabolism and nutrition disorders23/22527/23111/10013/101
COVID-19Infections and infestations20/22518/2315/10011/101
ArthralgiaMusculoskeletal and connective tissue disorders21/22512/2317/1004/101
NasopharyngitisInfections and infestations10/22518/2317/1009/101
HeadacheNervous system disorders17/22513/2318/1005/101
HypercholesterolaemiaMetabolism and nutrition disorders16/2257/2312/1005/101
Musculoskeletal painMusculoskeletal and connective tissue disorders4/2257/2316/1000/101
Vitamin D deficiencyMetabolism and nutrition disorders11/2259/2316/1003/101
OsteoarthritisMusculoskeletal and connective tissue disorders11/22511/2315/1006/101
Upper respiratory tract infectionInfections and infestations13/22512/2313/1005/101

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SB16ProliaTotal
<=18 years000
Between 18 and 65 years8995184
>=65 years136137273
Age, Continuous
Age, Continuous(years)SB16ProliaTotal
Mean66.5 ± 5.8766.3 ± 6.0366.4 ± 5.95
Sex: Female, Male
Sex: Female, Male(Participants)SB16ProliaTotal
Female225232457
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SB16ProliaTotal
American Indian or Alaska Native000
Asian182341
Native Hawaiian or Other Pacific Islander000
Black or African American000
White207208415
More than one race000
Unknown or Not Reported011
08

Study locations

5 sites
  • SB Investigative Site
    Kraków, Poland
  • SB Investigative Site
    Siedlce, Poland
  • SB Investigative Site
    Warszawa, Poland
  • SB Investigative Site
    Zamość, Poland
  • SB Investigative Site
    Łódź, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jun 2022, 18 months.

Results were first posted in Jan 2025, 2 years 6 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 18 months is below that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2020
First posted
Dec 11, 2020
StartActual
Nov 26, 2020
Primary completionActual
Jun 20, 2022
CompletionActual
Jan 3, 2023
Results first posted
Jan 9, 2025
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04664959
Responsible party
Sponsor
First posted
Dec 11, 2020
Start date
Nov 26, 2020
Primary completion
Jun 20, 2022
Completion
Jan 3, 2023
Results posted
Jan 9, 2025
Last update
Feb 4, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion